These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 22475314)
1. Theragnostic performance of ex vivo testing of haemostatic intervention and clinical effect of recombinant factor VIIa and fibrinogen concentrate. Tang M; Wierup P; Christiansen K; Greisen J; Sørensen B Thromb Res; 2012 May; 129(5):e263-5. PubMed ID: 22475314 [No Abstract] [Full Text] [Related]
9. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate. Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769 [TBL] [Abstract][Full Text] [Related]
10. Ex vivo reversal of the anticoagulant effects of edoxaban - comments on the study by Halim et al. Marlu R; Polack B; Pernod G Thromb Res; 2015 Mar; 135(3):571. PubMed ID: 25628140 [No Abstract] [Full Text] [Related]
11. Hemostatic effect of activated recombinant factor VIIa in Bernard-Soulier syndrome: studies in an in vitro model. Tonda R; Galán AM; Pino M; Lozano M; Ordinas A; Escolar G Transfusion; 2004 Dec; 44(12):1790-1. PubMed ID: 15584995 [No Abstract] [Full Text] [Related]
12. Ex vivo reversal of the anticoagulant effects of edoxaban. Halim AB; Samama MM; Mendell J Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520 [TBL] [Abstract][Full Text] [Related]
13. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood. Dirkmann D; Görlinger K; Gisbertz C; Dusse F; Peters J Anesth Analg; 2012 Jun; 114(6):1182-8. PubMed ID: 22104068 [TBL] [Abstract][Full Text] [Related]
14. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays. Brophy DF; Martin EJ; Barrett JC; Nolte ME; Kuhn JG; Hedner U; Ezban M Blood Coagul Fibrinolysis; 2011 Sep; 22(6):541-6. PubMed ID: 21681082 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram. Lak M; Scharling B; Blemings A; Sharifian R; Maleki Z; Daraee A; Arjmand AR; Hedner U Haemophilia; 2008 Jan; 14(1):103-10. PubMed ID: 18070065 [TBL] [Abstract][Full Text] [Related]
16. Hematologic effects of recombinant factor VIIa combined with hemoglobin-based oxygen carrier-201 for prehospital resuscitation of swine with severe uncontrolled hemorrhage due to liver injury. Arnaud F; Hammett M; Philbin N; Scultetus A; McCarron R; Freilich D Blood Coagul Fibrinolysis; 2008 Oct; 19(7):669-77. PubMed ID: 18832908 [TBL] [Abstract][Full Text] [Related]
17. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Tanaka KA; Taketomi T; Szlam F; Calatzis A; Levy JH Anesth Analg; 2008 Mar; 106(3):732-8, table of contents. PubMed ID: 18292410 [TBL] [Abstract][Full Text] [Related]
18. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients. Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865 [TBL] [Abstract][Full Text] [Related]
19. The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. Kjalke M; Oliver JA; Monroe DM; Hoffman M; Ezban M; Hedner U; Roberts HR Thromb Haemost; 1997 Oct; 78(4):1202-8. PubMed ID: 9364985 [TBL] [Abstract][Full Text] [Related]
20. Change in hemostatic intervention after implementation of thromboelastometry. Hvas AM; Boas TW; Jensen M; Lindskov C; Folkersen L; Ravn HB J Cardiothorac Vasc Anesth; 2012 Apr; 26(2):227-31. PubMed ID: 21924638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]